Comment on

• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Büller HR, et al. N Engl J Med. 2003 Oct 30;349(18):1695-702. doi: 10.1056/NEJMoa035451. N Engl J Med. 2003. PMID: 14585937 Clinical Trial.
• Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

  Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group. Francis CW, et al. N Engl J Med. 2003 Oct 30;349(18):1703-12. doi: 10.1056/NEJMoa035162. N Engl J Med. 2003. PMID: 14585938 Clinical Trial.
• Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

  Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators. Schulman S, et al. N Engl J Med. 2003 Oct 30;349(18):1713-21. doi: 10.1056/NEJMoa030104. N Engl J Med. 2003. PMID: 14585939 Clinical Trial.